Live Breaking News & Updates on Patient Understanding Leading

Update On SOURCE Phase 3 Trial For Tezepelumab In Patients With Severe, Oral Corticosteroid-Dependent Asthma
Amgen and AstraZeneca today announced the SOURCE trial did not meet the primary endpoint of a statistically significant reduction in the daily oral corticosteroid dose, without loss of asthma control, with tezepelumab compared to placebo. The 48-week trial assessed the efficacy and safety of the potential new medicine tezepelumab compared to placebo in 150 severe asthma patients who required maintenance use of oral …
Amgen (NASDAQ:AMGN) and AstraZeneca today announced the SOURCE trial did not meet the primary endpoint of a statistically significant reduction in the daily oral corticosteroid (OCS) dose, without loss of asthma control, with tezepelumab compared to placebo. ....

Puerto Rico , United States , United Kingdom , Lymphopoietin Isoforms , Megan Fox , Trish Rowland , Davidm Reese , Exchange Commission , Clinical Trial Program , Patient Care Research Database , Drug Administration , Beigene Ltd , Breakthrough Therapy Designation , Astrazeneca Collaboration , North America , Trial Program , Amgen Board , Thousand Oaks , Respir Rev , Thymic Stromal Lymphopoietin Isoforms , Inflammatory Disorders , Front Immunol , Uncontrolled Asthma , Patient Centered Description , Severe Asthma , Patient Understanding Leading ,